๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Treatment of recurrent hepatitis C in liver transplant recipients: Is there any histologic benefit?

โœ Scribed by Satheesh Nair; Saad Khan; George Loss; James Eason; Jamie Blazek; Jeanie Lipscomb; Andrew Mason

Book ID
111723346
Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
72 KB
Volume
9
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Treatment of hepatitis C in liver transp
Treatment of hepatitis C in liver transplant recipients
โœ Fredric D. Gordon; Paul Kwo; Hugo E. Vargas ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 182 KB ๐Ÿ‘ 1 views

Recurrent hepatitis C after liver transplantation is a universal phenomenon. Graft reinfection occurs rapidly; once it is established, allograft cirrhosis and decompensation rapidly ensue in many patients. Treatment with pegylated interferon plus ribavirin is the standard of care among nontransplant

Anemia in liver transplant recipients un
Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C
โœ Sammy Saab; Mina K. Oh; Ayman B. Ibrahim; Francisco Durazo; Steven Han; Hasan Ye ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 166 KB ๐Ÿ‘ 1 views

Adherence to antiviral therapy is essential to achieve sustained virological responses in patients treated for hepatitis C. An important limitation to use of appropriate doses of ribavirin is development of anemia. The aim of this study is to identify risk factors associated with anemia in liver tra